<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091492</url>
  </required_header>
  <id_info>
    <org_study_id>Vinforce_006</org_study_id>
    <secondary_id># 317.276.2000</secondary_id>
    <nct_id>NCT02091492</nct_id>
  </id_info>
  <brief_title>Teriparatide for Fracture Repair in Humans</brief_title>
  <acronym>TERAFRAP</acronym>
  <official_title>Teriparatide for Fracture Repair in Humans: A Prospective, Randomized, Double-blind Placebo-controlled Pilot Study in Female and Male Patients With Proximal Humerus Fracture: The TERAFRAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that daily subcuaneous administration of 20µg of&#xD;
      teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates&#xD;
      proximal 2-segment humerus fracture healing and improves the three dimensional structural&#xD;
      properties of bone as measured via quantitative bone image analysis and finite element&#xD;
      modeling assessed by quantitative computed tomography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary objective:&#xD;
&#xD;
           The primary objective is the quantitative assessment of fracture healing (2-segment&#xD;
           proximal humerus frafcture) in the treatment (daily teriapratide 20µg subcitaneous&#xD;
           injection for 12 weeks) and in the placebo group (daily placebo subcutaneous injection&#xD;
           for 12 weeks) based on computed tomography data (QCT; baseline and after 12 weeks) and&#xD;
           computational analysis of the three simensional bone structure in the fracture zone.&#xD;
           Bone structure will be assessed by means of quantized bone texture characteristics&#xD;
           (callus formation, improvement of trabecualar and cortical bone structure) in the&#xD;
           vicinity of the fracture.&#xD;
&#xD;
        2. Secondary objectives:&#xD;
&#xD;
      2.1.Detection and quantification of changes in bone mineralization at the fracture site&#xD;
      between a baseline QCT scan and a follow-up QCT scan (planned interval: 12 weeks) using 3-D&#xD;
      texture-based cluster analysis between the two groups.&#xD;
&#xD;
      2.2 Evaluation of bone strength variation in the proximal humerus and the measurement of&#xD;
      biomechanical properties (stiffness, strength, damage) based on the Finite Element (FE)&#xD;
      technique between the two groups.&#xD;
&#xD;
      2.3.Baseline characterization of osteoporotic study population: age, sex, concomitant&#xD;
      diseases, serum markers of bone formation and bone resorption, serum colecalciferol levels.&#xD;
&#xD;
      2.4.Evaluation of fasting bone formation and resorption markers at baseline and after 3&#xD;
      months follow up between the TPDT and the placebo group.&#xD;
&#xD;
      2.5.Assessment of quality of life improvement for TPTD and placebo groups with EQ-5D&#xD;
      questionnaire (measurement every 4 weeks).&#xD;
&#xD;
      2.6.Assessment of pain reduction in TPTD and placebo groups by visual analog scale (VAS)&#xD;
      during 12 weeks (measurement every 4 weeks).&#xD;
&#xD;
      2.7.Assessment of functional testing after 3 and 6 months (functional testing score (ASES&#xD;
      Score: &quot;American Shoulder and Elbow Surgeon Score&quot;)&#xD;
&#xD;
      2.8.Dual energy x-ray absorptiometry (DXA) bone mineral density (BMD) measurements of lumbar&#xD;
      spine and early changes of geometrical hip parameters (cross sectional area - CSA, cross&#xD;
      sectional moment of inertia - CSMI), hip BMD(femoral neck and total hip area) and total body&#xD;
      (lean mass, fat mass, total body BMD)&#xD;
&#xD;
      2.9. Number of Participants with Adverse Events as a Measure of Safety and Tolerability&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no participants&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of bone and callus patterns in the CT data at the fracture site</measure>
    <time_frame>12 weeks</time_frame>
    <description>As a basis for change quantification, we will identify 3D micro-architecture patterns that occur in the study CT data. These patterns are either learned based on annotated examples, manual segmentation of specific regions in a number of reference examples, or in a data-driven fashion (computer based identification of pattern classes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Finite Element Analysis (FEA) of QCT (quantitative computed tomography) data</measure>
    <time_frame>12 weeks</time_frame>
    <description>The FEA Method will be a second diagnostic tool in order to evaluate the change in bone strength in the proximal humerus during treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tracking geometry during bone healing</measure>
    <time_frame>12 weeks</time_frame>
    <description>The extent of bridging and callus formation will be quantified, based on the voxel-wise comparison of follow-up data. The accumulated density difference between baseline and follow-up over a region of interest serves as parameter.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoporosis, Age-Related</condition>
  <condition>Humeral Fractures</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Teriparatide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks</description>
    <arm_group_label>Teriparatide</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks</description>
    <arm_group_label>Placebo-Teriparatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recent proximal 2-segment humerus fracture (0-8 days post fracture)&#xD;
&#xD;
          -  no surgical treatment at fractured site&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  postmenopausal female and male patients aged 60 - 85 years&#xD;
&#xD;
          -  established osteoporosis as defined by BMD measured with DXA-technology (dual energy&#xD;
             X-ray absorptiometry) with a T-score ≤ -2.0 spine or hip&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients.&#xD;
&#xD;
          -  Pre-existing hypercalcemia&#xD;
&#xD;
          -  Severe renal impairment (eGFR&lt; 35ml/min)&#xD;
&#xD;
          -  Metabolic bone diseases (including hyperparathyroidism and Paget's disease of the&#xD;
             bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.&#xD;
&#xD;
          -  Unexplained elevations of alkaline phosphatase&#xD;
&#xD;
          -  Prior external beam or implant radiation therapy to the skeleton&#xD;
&#xD;
          -  Patients with skeletal malignancies or bone metastases should be excluded from&#xD;
             treatment with teriparatide.&#xD;
&#xD;
          -  any prior antiresorptive therapy (oral/intravenous bisphosphonates, RANKL-antibody,&#xD;
             SERMs)&#xD;
&#xD;
          -  any prior strontium ranelate therapy&#xD;
&#xD;
          -  any prior TPTD of PTH 1-84 therapy&#xD;
&#xD;
          -  malignancies ≤ 5 years except basalioma&#xD;
&#xD;
          -  hypo-/hypercalcemia&#xD;
&#xD;
          -  baseline 25-OH vitamin D3 level ≤10 ng/ml&#xD;
&#xD;
          -  prosthesis at fractured and contralateral humerus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Muschitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna, St. Vincent Hospital Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna; St. Vincent Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.vinforce.at</url>
    <description>Homepage of Research Team</description>
  </link>
  <reference>
    <citation>Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010 Apr;81(2):234-6. doi: 10.3109/17453671003761946. Erratum in: Acta Orthop. 2010 Oct;81(5):647.</citation>
    <PMID>20367417</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Christian Muschitz</investigator_full_name>
    <investigator_title>Senior Consultant for Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Proximal humerus fracture, teriparatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Humeral Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

